RBC Capital Reinstates Outperform on Bio-Techne, Announces $62 Price Target
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
RBC Capital analyst Dan Leonard reinstates Bio-Techne (NASDAQ:TECH) with a Outperform and announces $62 price target.
RBC Capital analyst Dan Leonard reinstates Bio-Techne (NASDAQ:TECH) with a Outperform and announces $62 price target.